[Possibilities of optimizing therapy in COVID-19 survivors with focal epilepsy].
作者信息
Ponomareva I V, Stepanova S B, Reneva S A, Sorokova E V, Vagina M A, Makodzeba O A, Galiullin T R
机构信息
Chelyabinsk Regional Clinical Hospital No. 3, Chelyabinsk, Russia.
South Ural State Medical University, Chelyabinsk, Russia.
出版信息
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(3):130-136. doi: 10.17116/jnevro2023123031130.
OBJECTIVE
To study the effect of phenosanoic acid therapy on the frequency of seizures, asthenia and quality of life of adult patients with focal epilepsy who had a new coronavirus infection caused by SARS-CoV-2.
MATERIAL AND METHODS
The data of 20 patients with focal epilepsy who suffered COVID-19 and received therapy with phenosanic acid (Dibufelon) were studied. The frequency of epileptic seizures, the severity of asthenia and the quality of life were evaluated according to clinical scales.
RESULTS
Significant decrease in the frequency of bilateral tonic-clonic seizures and focal seizures with loss of consciousness was recorded. There was a significant improvement in the quality of life. There was no significant dynamics of asthenia against the background of taking the drug phenosanic acid in patients.
CONCLUSION
The preparation of phenosanic acid can be an effective means of add-on therapy in patients with epilepsy who have undergone COVID-19.
Zotero 插件